124 related articles for article (PubMed ID: 9233651)
1. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.
Ekholm D; Hemmer B; Gao G; Vergelli M; Martin R; Manganiello V
J Immunol; 1997 Aug; 159(3):1520-9. PubMed ID: 9233651
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
5. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study.
Oelke M; Hedlund P; Albrecht K; Ellinghaus P; Stief CG; Jonas U; Andersson KE; Uckert S
Urology; 2006 May; 67(5):1111-6. PubMed ID: 16635522
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
Liu H; Maurice DH
Br J Pharmacol; 1998 Dec; 125(7):1501-10. PubMed ID: 9884079
[TBL] [Abstract][Full Text] [Related]
7. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
8. Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Murata T; Shimizu K; Narita M; Manganiello VC; Tagawa T
Anticancer Res; 2002; 22(6A):3171-4. PubMed ID: 12530061
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactivity of myelin basic protein-specific T cells with multiple microbial peptides: experimental autoimmune encephalomyelitis induction in TCR transgenic mice.
Grogan JL; Kramer A; Nogai A; Dong L; Ohde M; Schneider-Mergener J; Kamradt T
J Immunol; 1999 Oct; 163(7):3764-70. PubMed ID: 10490973
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
13. Expression of the cAMP-phosphodiesterase PDE4D isoforms and age-related changes in follicle-stimulating hormone-stimulated PDE4 activities in immature rat sertoli cells.
Levallet G; Levallet J; Bouraïma-Lelong H; Bonnamy PJ
Biol Reprod; 2007 May; 76(5):794-803. PubMed ID: 17215491
[TBL] [Abstract][Full Text] [Related]
14. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.
Bielekova B; Lincoln A; McFarland H; Martin R
J Immunol; 2000 Jan; 164(2):1117-24. PubMed ID: 10623864
[TBL] [Abstract][Full Text] [Related]
16. IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells.
Ahmad F; Gao G; Wang LM; Landstrom TR; Degerman E; Pierce JH; Manganiello VC
J Immunol; 1999 Apr; 162(8):4864-75. PubMed ID: 10202031
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
19. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.
Narita M; Murata T; Shimizu K; Nakagawa T; Sugiyama T; Inui M; Hiramoto K; Tagawa T
Oncol Rep; 2007 May; 17(5):1133-9. PubMed ID: 17390056
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclic nucleotide phosphodiesterase 3A in isolated rat submandibular acini.
Shimizu K; Murata T; Hiramoto K; Sugiyama T; Nakagawa T; Manganiello VC; Tagawa T
Arch Oral Biol; 2006 Feb; 51(2):83-8. PubMed ID: 16102722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
